Cargando…

Prognostic Impact of Immunohistochemical p53 Expression in Bone Marrow Biopsy in Higher Risk MDS: a Pilot Study

BACKGROUND AND OBJECTIVES: Mutations of the TP53 gene have an unfavorable prognosis in Myelodysplastic Syndromes (MDS). The product of the TP53 gene is the p53 protein. Most of the TP53 mutations entail the accumulation of the protein in the nucleus of tumor cells. The immunohistochemical (IHC) stai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molteni, Alfredo, Ravano, Emanuele, Riva, Marta, Nichelatti, Michele, Bandiera, Laura, Crucitti, Lara, Truini, Mauro, Cairoli, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402551/ https://www.ncbi.nlm.nih.gov/pubmed/30858953 http://dx.doi.org/10.4084/MJHID.2019.015

Ejemplares similares

CD34 and p53 Immunohistochemical Stains Differentiate Hypocellular Myelodysplastic Syndrome (hMDS) from Aplastic Anemia and a CD34 Immunohistochemical Stain Provides Useful Survival Information for hMDS
por: Cha, Choong-Hwan, et al.
Publicado: (2014)

Are We Ready For “Triplet” Therapy in Higher-Risk MDS?
por: Brunner, Andrew M., et al.
Publicado: (2023)

Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts
por: Yahng, Seung-Ah, et al.
Publicado: (2016)

Nilotinib‐induced bone marrow CD34+/lin‐Ph+ cells early clearance in newly diagnosed CP‐Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study
por: Pungolino, Ester, et al.
Publicado: (2021)

Targeting p53 in MDS: Highlights From SOHO 2021
Publicado: (2022)

P53 IHC Result as a Prognostic Tool in MDS
por: Rezvani, Alireza, et al.
Publicado: (2023)

Bone Marrow Defects and Platelet Function: A Focus on MDS and CLL
por: Luu, Sarah, et al.
Publicado: (2018)

A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Extensively Studied by Flow Cytometry and Immunohistochemistry
por: Pennisi, Martina, et al.
Publicado: (2017)

MDS and TP53: When One Hit Just Isn’t Enough…
por: Kent, David G.
Publicado: (2020)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review
por: Zilioli, Vittorio Ruggero, et al.
Publicado: (2023)

Consistency of P53 immunohistochemical expression between preoperative biopsy and final surgical specimens of endometrial cancer
por: Zhang, Jun, et al.
Publicado: (2023)

Utility of 5-Methylcytosine Immunohistochemical Staining to Assess Global DNA Methylation and Its Prognostic Impact in MDS Patients
por: Chandra, Dinesh, et al.
Publicado: (2017)

Iron Overload Impairs Bone Marrow Mesenchymal Stromal Cells from Higher-Risk MDS Patients by Regulating the ROS-Related Wnt/β-Catenin Pathway
por: Huang, Lei, et al.
Publicado: (2020)

A double‐hit High‐grade B‐cell lymphoma with three‐way translocation t(3;8;14)(q27;q24;q32) involving BCL6, MYC, and IGH
por: De Paoli, Elena, et al.
Publicado: (2018)

PB1989: STUDY ON THE RELATIONSHIP BETWEEN MDS AND ABNORMAL LIPID METABOLISM IN BONE MARROW MICROENVIRONMENT
por: LI, Yuchun, et al.
Publicado: (2023)

P703: THE AIPSS-MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF THE SPANISH REGISTRY OF MDS
por: Mosquera-Orgueira, Adrian, et al.
Publicado: (2023)

P699: MAGROLIMAB ALTERS THE TUMOR MICROENVIRONMENT TO IMPROVE BONE MARROW FUNCTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)
por: Johnson, Lisa, et al.
Publicado: (2023)

Diagnosis and Classification of Acute Leukemia in Bone Marrow Trephine Biopsies, Utility of a Selected Panel of Minimal Immunohistochemical Markers
por: Subashchandrabose, Priya, et al.
Publicado: (2016)

MDS shows a higher expression of hTERT and alternative splice variants in unactivated T-cells
por: Dong, Wen, et al.
Publicado: (2016)

ATS MD’s in 2016
por: Fartoukh, Stephane, et al.
Publicado: (2016)

Software needs for MDs
por: Ruggiero, F
Publicado: (1993)

LHC MDS For 2018
por: Tomás, R, et al.
Publicado: (2019)

Bogus "M.Ds."
por: Karnik, C. H.
Publicado: (1929)

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
por: Sallman, David A., et al.
Publicado: (2016)

Quantification of Immunohistochemically Stained Cells in Skin Biopsies
por: Emmanuel, Thomas, et al.
Publicado: (2022)

Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts
por: Poulaki, Aikaterini, et al.
Publicado: (2020)

Clonal MDS/AML cells with enhanced TWIST1 expression reprogram the differentiation of bone marrow MSCs
por: Li, Hongjiao, et al.
Publicado: (2023)

Molecular and immunohistochemical analysis of P53 in phaeochromocytoma.
por: Dahia, P. L., et al.
Publicado: (1995)

Bone Marrow Biopsy
por: Haworth, C.
Publicado: (1982)

Bone Marrow Biopsy
Publicado: (1949)

Isolated Myeloperoxidase Immunohistochemical Expression in Bone Marrow Biopsy Depicts Clinical Outcomes in Adults with Typical B-Acute Lymphoblastic Leukemia
por: Fawzy, Maha Mohamed, et al.
Publicado: (2021)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

PB1999: TOBACCO SMOKING IN MDS PATIENTS – ANALYSIS FROM THE MDS PALG REGISTRY
por: Machowicz, Rafal, et al.
Publicado: (2023)

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
por: Zeidan, Amer M., et al.
Publicado: (2018)

Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression
por: Weickert, Marie-Theresa, et al.
Publicado: (2021)

PS Beams for SPS MDs
por: Manglunki, Django
Publicado: (1998)

p38 MAPK in MDS
por: Gañán‐Gómez, Irene, et al.
Publicado: (2015)

William Jarvie, M.D.S.
Publicado: (1922)

Cannot write session to /tmp/vufind_sessions/sess_4eo727unr2upp1aapt8ko2ln7k